MREO Mereo BioPharma Group PLC

2.94

0.06 (2.08%)

14 Feb 2025 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Mereo BioPharma Group PLC	NASDAQ:MREO	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.06	2.08%	2.94	2.83	2.94	2.97	2.84	2.91	897,716	23:56:10

Form 144 - Report of proposed sale of securities

12/09/2024 9:05pm

Edgar (US Regulatory)

="/Images/box-unchecked.jpg" alt="Checkbox not checked">16403709/12/2024Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds

Alexandra Hughes-Wilson
4th Floor, One Cavendish Place
London � X0 � W1G 0QF

American Depositary Shares Representing Ordinary Shares

06/25/2024

10134

37433.98

Alexandra Hughes-Wilson
4th Floor, One Cavendish Place
London � X0 � W1G 0QF

American Depositary Shares Representing Ordinary Shares

06/26/2024

22968

77935.02

144: Remarks and Signature

Remarks

The number of shares to be sold is in the form of American Depositary Shares ("ADSs"). The number of shares outstanding is in the form of ordinary shares. Each ADS represents 5 ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Date of Notice

09/12/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Alexandra Hughes-Wilson